Argenx Se (ARGX) EBT Growth (1y) (2017 - 2026)
Powered by 
Analysis
Argenx Se (ARGX) EBT Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 8.48% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 0.60% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 88.92% |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 6.23% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 213.87% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 530.43% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -12.04% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 96.45% |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | 34.68% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 88.92% |
| Mar 31, 2026 | 116.94% |
| Dec 31, 2025 | 380.97% |
| Sep 30, 2025 | 338.58% |
| Jun 30, 2025 | 2,012.28% |
| Mar 31, 2025 | 372.17% |
| Dec 31, 2024 | 237.06% |
| Sep 30, 2024 | 205.70% |
| Jun 30, 2024 | 82.11% |
| Mar 31, 2024 | 2.40% |
| Dec 31, 2023 | -48.35% |
| Sep 30, 2023 | 65.45% |
| Jun 30, 2023 | 61.35% |
| Mar 31, 2023 | 66.89% |
| Dec 31, 2022 | 83.16% |
| Sep 30, 2022 | -4.40% |
| Jun 30, 2022 | -306.15% |
| Mar 31, 2022 | -686.60% |
| Dec 31, 2021 | -123.16% |
| Sep 30, 2021 | -25.73% |